Paratek Pharmaceuticals Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Paratek Pharmaceuticals's estimated annual revenue is currently $17.1M per year.(i)
  • Paratek Pharmaceuticals received $50.0M in venture funding in January 2018.
  • Paratek Pharmaceuticals's estimated revenue per employee is $65,084
  • Paratek Pharmaceuticals's total funding is $133M.

Employee Data

  • Paratek Pharmaceuticals has 263 Employees.(i)
  • Paratek Pharmaceuticals grew their employee count by -12% last year.

Paratek Pharmaceuticals's People

FounderReveal Email/Phone
Chief Development and Regulatory OfficeReveal Email/Phone
Executive Director, National Sales Government Accounts at Paratek PharmaceuticalsReveal Email/Phone
CEOReveal Email/Phone
VP, FinanceReveal Email/Phone
VP, Head Digital Information and Strategic SolutionsReveal Email/Phone
Head Biothreat ResearchReveal Email/Phone
VP Medical And Scientific StrategyReveal Email/Phone
VP, Market Access, Trade and Government AffairsReveal Email/Phone
VP Regulatory Affairs Quality and ManufacturingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Paratek Pharmaceuticals?

Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. We focus on drugs that target infectious disease and other difficult to treat conditions. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Paratek Pharmaceuticals News

2022-04-17 - Zacks: Analysts Expect Paratek Pharmaceuticals, Inc ...

Zacks: Analysts Expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to Announce -$0.35 Earnings Per Share. Posted by admin on Apr 21st, 2022.

2022-04-17 - Where Will Paratek Pharmaceuticals Inc (PRTK) Stock Go Next After It Has Fallen 9.80% in a Week?

PRTK gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bearish. Paratek Pharmaceuticals Inc has a...

2022-04-13 - Do Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Stock to Rise After It Is Lower By -14.42% in a Month?

Do Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Stock to Rise After It Is Lower By -14.42% in a Month? Thursday, April 14, 2022 10:45 AM |...

2021-06-01 - PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-sta ...

2019-09-08 - Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Buckles ...

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) stock has been on a recent steady downtrend, causing some concern for shareholders.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Paratek Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2008-04-17$40.0MUndisclosedAisling Capital, D.E. Shaw GroupArticle
2015-04-29$69.0MUndisclosedLeerink PartnersArticle
2018-01-19$50.0MUndisclosedBTIG, LLCArticle